A Randomised Controlled Trial Of Normoglycaemia Versus Conventional Glycaemic Control In Intensive Care Unit Patients.
Funder
National Health and Medical Research Council
Funding Amount
$1,773,507.00
Summary
The concentration of sugar in the blood is often increased in patients in intensive care and patients with increased blood sugar levels are more likely to die. A recent study performed in a Belgian intensive care unit found that using high doses of insulin to lower blood sugars levels to normal increased the number of patients who survived. The chance of surviving to leave hospital was increased from 89% to 93%. Whilst the result is very encouraging, Intensive Care Specialists in Australia are u ....The concentration of sugar in the blood is often increased in patients in intensive care and patients with increased blood sugar levels are more likely to die. A recent study performed in a Belgian intensive care unit found that using high doses of insulin to lower blood sugars levels to normal increased the number of patients who survived. The chance of surviving to leave hospital was increased from 89% to 93%. Whilst the result is very encouraging, Intensive Care Specialists in Australia are unsure if the treatment would work in their patients because of differences in the types of patients found in intensive care units in Australia, and because of other treatment given to the patients in the Belgian study. In particular the doctors in the Belgian unit studied only patients who had had operations and gave large amounts of intravenous sugar to their patients. This is not normally done in Australian Intensive Care Units and the safety of giving high dose insulin to patients not receiving large amounts of intravenous sugar is not known. This is of particular interest as reducing blood glucose to abnormally low levels can cause serious side effects and even result in permanent brain damage. The Australian and New Zealand Intensive Care Society proposes to conduct a new study involving 4,000 patients from intensive care units in Australia and New Zealand and will study all patients regardless of whether or not they have had an operation. These patients will be randomly assigned to receive insulin to control blood sugar levels to normal or to slightly above normal levels as has been tradition in intensive care units around the world. Outcome and serious side effects will be closely monitored. The results will be available within three years of starting the study, and these are likely to influence the treatment of the majority of patients admitted to intensive care units both in Australia and worldwide.Read moreRead less
Long Acting Insulin: Drug Design, In Vitro Activity Through To Animal Model Efficacy
Funder
National Health and Medical Research Council
Funding Amount
$445,011.00
Summary
This research will develop novel insulins that possess improved stability and activity for diabetic patients. The improved pharmacological actions of the modified insulins offer increased treatment options for patients eg. enabling less frequent or invasive medication. Our cross-disciplinary team will (i) design and synthesise insulin derivatives, (ii) explore the activity of the modified insulins by biophysical activity profiles in vitro, (iii) evaluate the in vivo stability and clinical effect ....This research will develop novel insulins that possess improved stability and activity for diabetic patients. The improved pharmacological actions of the modified insulins offer increased treatment options for patients eg. enabling less frequent or invasive medication. Our cross-disciplinary team will (i) design and synthesise insulin derivatives, (ii) explore the activity of the modified insulins by biophysical activity profiles in vitro, (iii) evaluate the in vivo stability and clinical effects.Read moreRead less
The amyloid beta (Ab) protein is implicated in Alzheimer’s Disease through its ability to impair brain metabolism. We have recently found that Ab can also impair metabolism in other tissues. This project will determine the role of Ab in regulating whole body metabolism and determine whether it is implicated in the development of metabolic diseases such as type 2 diabetes.
Conologues: Ultra-fast-acting Therapeutic Insulins Based On Cone Snail Venom Insulin Principles
Funder
National Health and Medical Research Council
Funding Amount
$1,082,866.00
Summary
The increasing prevalence of Type 1 and Type 2 diabetes demands better treatments. Our Project is based on a fascinating discovery by our international team of CIs of a new type of insulin within marine organisms that could form the basis of a novel diabetes therapeutic. Within our Project we will exploit this discovery to develop a new class of ultra-rapid-acting therapeutic insulins.
In 2011 there were over 360 million people with type 1 and type 2 diabetes worldwide, who will require insulin treatment. There is an urgent need for insulin analogues that provide effective control of blood glucose to avoid unwanted hypoglycemic or hyperglycemic events. We have developed two novel insulin analogues with unique properties and aim to understand their mechanism of action. This knowledge will present new opportunities for improved insulin mimetics for diabetes treatment.
Metabolic Wiring In Adipocytes - Unique Role In Maintaining Long-term Health
Funder
National Health and Medical Research Council
Funding Amount
$1,077,886.00
Summary
Fat cell metabolism is wired to optimize the cell’s ability to make and store lipid while programming the cell to fulfil its function in whole body metabolism. We will: 1) map fat cell metabolism under optimal and insulin resistant conditions; 2) explore the role of 3 nodes in his metabolic circuit predicted as control points; 3) use a novel genetically engineered mouse model to explore the functional significance of fat cell metabolism in whole body insulin sensitivity.
The prevalence of type 2 diabetes in increasing worldwide, the International Diabetes Federation predicting 435 million will have diabetes in 2030. The major driver of the diabetes epidemic is obesity. There is strong evidence linking type 2 diabetes and obesity to an increased risk of cancer. However, the exact mechanism promoting cancer development in obese and diabetic individuals is not clear. This project will examine the effects of high insulin levels on cancer development and progression.
The Role Of Vitamin D In Beta Cell Function, Glucose Tolerance And Diabetes Mellitus.
Funder
National Health and Medical Research Council
Funding Amount
$102,820.00
Summary
A significant proportion of Australians are deficient in Vitamin D, a vitamin obtained from sunlight exposure and to a lesser extent from food. Vitamin D deficiency has been associated with increased risk of Type 2 diabetes. This study aims to demonstrate the mechanisms through which vitamin D affects the insulin-producing cells of the pancreas and to determine whether deficiency affects the body's handling of glucose and subsequent risk of Type 2 diabetes and diabetes in pregnancy.
Dissecting The Role Of Selective Insulin Resistance In Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$980,624.00
Summary
Insulin resistance is a clinical condition where insulin, secreted from the pancreas in response to meals, is unable to fulfill its normal function. It is intimately linked to obesity and associated diseases - type 2 diabetes, cancer and cardiovascular disease. This proposal examines mechanisms contributing to insulin resistance and how insulin resistance leads to disease. We will identify drug targets with improved specificity and lead to novel insight into the risks of current treatments.
Targeting The Insulin And Insulin-like Growth Factor Receptors In Cancer, Diabetes And Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$993,251.00
Summary
Diabetes, cancer and Alzheimer's disease are three major diseases facing Australia. This Project will investigate a common point-of-focus of these diseases, namely the interaction of insulin and the insulin-like growth factors with their receptor molecules on the cell surface. It will use recent breakthrough findings by the Chief Investigators to develop new therapeutic approaches for these diseases that could function by targeting these interactions.